Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
51 studies found for:    Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate OR Stribild[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Recruiting Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
Condition: HIV-1 Infection
Intervention: Drug: E/C/F/TAF
22 Recruiting HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Conditions: Human Immunodeficiency Virus;   Hepatitis C, Chronic
Interventions: Drug: E/C/F/TAF;;   Drug: Ledipasvir-Sofosbuvir
23 Recruiting STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)
Conditions: HIV;   Illicit Drug User
Intervention: Drug: STRIBILD
24 Completed Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
Condition: HIV Disease
Intervention: Drug: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
25 Completed Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Conditions: Hepatitis C Infection;   HIV Infection
Intervention: Drug: Sofosbuvir, Ribavirin, and Stribild
26 Completed
Has Results
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: COBI;   Drug: ATV;   Drug: DRV;   Drug: NRTI
27 Active, not recruiting Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Condition: HIV Infection
Intervention: Drug: Treatment simplification
28 Recruiting HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
Condition: HIV
Intervention: Drug: Atripla or Stribild
29 Completed Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination
Condition: Healthy
Interventions: Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC;   Drug: Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC;   Drug: Darunavir;   Drug: Emtricitabine/Tenofovir alafenamide (FTC/TAF);   Drug: Cobicistat;   Other: High-fat Breakfast;   Other: Standardized Regular Breakfast
30 Active, not recruiting Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Conditions: HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: TAF;   Drug: Placebo to match TAF;   Drug: E/C/F/TAF;   Drug: Pre-existing ARV regimen;   Drug: ATV
31 Active, not recruiting Renal Integrase Study
Condition: HIV
Interventions: Drug: Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat);   Drug: Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet;   Drug: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
32 Active, not recruiting Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention: Drug: E/C/F/TAF
33 Completed Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
Condition: HIV-1 Infection
Interventions: Drug: STB;   Drug: TVD;   Drug: ATR;   Drug: RTV;   Drug: ATV;   Drug: ABC/3TC;   Drug: Iohexol
34 Completed Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Conditions: HIV-1;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: E/C/F/TAF;   Drug: DRV;   Drug: Pre-existing ARV regimen
35 Completed Interaction With HIV Antiretroviral Agents
Condition: HIV-DDI
Interventions: Drug: Riociguat (ADEMPAS);   Drug: ATRIPLA;   Drug: COMPLERA;   Drug: STRIBILD;   Drug: TRIUMEQ;   Drug: Antiretroviral protease inhibitor
36 Completed Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet
Condition: HIV
Interventions: Drug: Stribild;   Drug: Stribild, crushed
37 Completed Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication
Condition: Insulin Resistance
Interventions: Drug: Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat;   Drug: Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir;   Drug: Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
38 Recruiting Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
Conditions: Patient Compliance;   Antiretroviral Therapy Intolerance
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir;   Drug: Darunavir;   Drug: abacavir/lamivudine;   Drug: Ritonavir;   Drug: Lamivudine;   Drug: rilpivirine
39 Recruiting Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Conditions: HIV-1 Infection;   HCV Infection
Interventions: Drug: E/C/F/TAF;   Drug: F/R/TAF;   Drug: LDV/SOF
40 Active, not recruiting Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results    Last Page
Indicates status has not been verified in more than two years